Pei-Yong Shi

Apr 8, 2024 | nature.com | Xuping Xie |Hongtao Yu |Jing Huang |Pei-Yong Shi

AbstractDrug resistance poses a significant challenge in the development of effective therapies against SARS-CoV-2. Here, we identified two double mutations, M49K/M165V and M49K/S301P, in the 3C-like protease (3CLpro) that confer resistance to a novel non-covalent inhibitor, WU-04, which is currently in phase III clinical trials (NCT06197217).

Jan 1, 2024 | nature.com | Jiakai Hou |Yanjun Wei |Long Sun |Shaoheng Liang |Ashley Guerrero |Xiaobo Mao | +7 more

AbstractHost anti-viral factors are essential for controlling SARS-CoV-2 infection but remain largely unknown due to the biases of previous large-scale studies toward pro-viral host factors. To fill in this knowledge gap, we perform a genome-wide CRISPR dropout screen and integrate analyses of the multi-omics data of the CRISPR screen, genome-wide association studies, single-cell RNA-Seq, and host-virus proteins or protein/RNA interactome.

Dec 10, 2023 | nature.com | Ching-Lin Hsieh |Andrew Horton |Xuping Xie |Hongjie Xia |Pei-Yong Shi |Andrew D Ellington | +7 more

AbstractThe ongoing evolution of SARS-CoV-2 into more easily transmissible and infectious variants has provided unprecedented insight into mutations enabling immune escape. Understanding how these mutations affect the dynamics of antibody-antigen interactions is crucial to the development of broadly protective antibodies and vaccines. Here we report the characterization of a potent neutralizing antibody (N3-1) identified from a COVID-19 patient during the first disease wave.

Oct 20, 2023 | nature.com | Jason Yeung |Pei-Yong Shi |Xuping Xie

AbstractAn attenuated SARS-CoV-2 virus with modified viral transcriptional regulatory sequences and deletion of open-reading frames 3, 6, 7 and 8 (∆3678) was previously reported to protect hamsters from SARS-CoV-2 infection and transmission. Here we report that a single-dose intranasal vaccination of ∆3678 protects K18-hACE2 mice from wild-type or variant SARS-CoV-2 challenge.

Jun 16, 2023 | journals.aai.org | Pei-Yong Shi

A.-C.G. has received research funds from a research contract with Providence Therapeutics Holdings, Inc., for other projects, participated in the COVID-19 Immunity Task Force Immune Science and Testing working party, chaired the Canadian Institutes of Health Research Institute of Genetics Advisory Board, and chairs the Science Advisory Board of the National Research Council of Canada Human Health Therapeutics Board.